Interim report
Page 1
August 6 , 2026 Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31 , 2027 ( Three Months Ended June 30 , 2026 ) Company name : ROHTO PHARMACEUTICAL CO . , LTD . FASF [ Japanese GAAP ] Listing : Tokyo Stock Exchange Securities code : 4527 URL : https://www.rohto.co.jp/ Representative : Hidetoshi Segi Inquiries : Masaya Saito Telephone : + 81-6-6758-8223 Scheduled date to commence dividend payments : - President and Representative Director Executive Vice President and CFO Preparation of supplementary material on financial results : Yes Holding of financial results briefing : Yes ( for institutional investors and analysts ) ( Yen amounts are rounded down to millions , unless otherwise noted . ) 1. Consolidated financial results for the three months ended June 30 , 2026 ( from April 1 , 2026 to June 30 , 2026 ) ( 1 ) Consolidated operating results ( cumulative ) ( Percentages indicate year - on - year changes . ) Net sales Operating income Three months ended June 30 , 2026 Millions of yen 91,624 % 11.8 Millions of yen 13,663 % Ordinary income Millions of yen 16.8 14,491 June 30 , 2025 81,964 19.9 11,699 ( 0.8 ) 16,127 % ( 10.1 ) 31.4 Profit attributable to owners of parent Millions of yen % 10,650 ( 9.5 ) 11,769 38.7 Note : Comprehensive income For the three months ended June 30 , 2026 : For the three months ended June 30 , 2025 : ¥ 13,929 million [ 79.3 % ] ¥ 7,769 million [ ( 51.7 ) % ] Diluted net income Net income per share per share Three months ended June 30 , 2026 Yen 47.14 52.09 Yen 46.50 51.39 June 30 , 2025 ( 2 ) Consolidated financial position As of June 30 , 2026 March 31 , 2026 Reference : Equity Total assets Net assets Equity - to - asset ratio Millions of yen 487,151 485,771 Millions of yen % 328,459 320,174 63.5 62.1 As of June 30 , 2026 : As of March 31 , 2026 : 2. Cash dividends ¥ 309,106 million ¥ 301,446 million Fiscal year ended March 31 , 2026 Fiscal year ending March 31 , 2027 First quarter - end Second quarter - end Third quarter - end Yen Annual dividends per share Fiscal year - end Total Yen 21.00 Yen Yen Yen 25.00 46.00 Fiscal year ending March 31 , 2027 25.00 ( Forecast ) Note : Revisions to the forecast of cash dividends most recently announced : None 25.00 50.00
Page 2
3. Consolidated financial result forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027) (Percentages indicate year-on-year changes.) Net sales Operating income Ordinary income Profit attributable to owners of parent Net income per share Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen Full year 372,300 8.3 45,000 9.4 47,400 (1.2) 35,200 2.8 155.78 Note: Revisions to the financial result forecast most recently announced: Yes * Notes (1) Significant changes in the scope of consolidation during the period: None Newly included: - companies( ) Excluded: - companies( ) (2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes Note: Please refer to page 8 of the attachments "2. Quarterly Consolidated Financial Statements and Major Notes, (3) Notes to Quarterly Consolidated Financial Statements" for further information. (3) Changes in accounting policies, changes in accounting estimates, and restatement (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None (ii) Changes in accounting policies due to other reasons: None (iii) Changes in accounting estimates: None (iv) Restatement: None (4) Number of issued shares (common shares) (i) Total number of issued shares at the end of the period (including treasury shares) As of June 30, 2026 236,178,310 shares As of March 31, 2026 236,178,310 shares (ii) Number of treasury shares at the end of the period As of June 30, 2026 10,214,018 shares As of March 31, 2026 10,214,018 shares (iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year) Three months ended June 30, 2026 225,964,292 shares Three months ended June 30, 2025 225,964,374 shares * Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None *Cautionary statement with respect to forward-looking statements and other special items Forecasts regarding future performance in these materials are based on assumptions judged to be valid and information available to the Company at the time the materials were created. These materials are not promises by the Company regarding future performance. Actual results of operations may differ significantly from the forecasts depending on various factors. For discussion of the assumptions and other factors considered by the Company in preparing the above projections, please refer to page 3 of the at tachments "1. Qualitative Information on Quarterly Consolidated Financial Performance, (3) Explanation of Consolidated Earnings Forecast and Other Forward-looking Statements."
Page 3
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―1― Contents of Attachments 1. Qualitative Information on Quarterly Consolidated Financial Performance 2 (1) Explanation of Results of Operations 2 (2) Explanation of Financial Position 3 (3) Explanation of Consolidated Earnings Forecast and Other Forward -looking Statements 3 2. Quarterly Consolidated Financial Statements and Major Notes 4 (1) Quarterly Consolidated Balance Sheets 4 (2) Quarterly Consolidated Statements of Income and Comprehensive Income 6 (3) Notes to Quarterly Consolidated Financial Statements 8 Application of Special Accounting Methods for Preparation of Quarterly Consolidated Financial Statements 8 Segment Information 9 Significant Changes in Shareholders’ Equity 10 Going Concern Assumption 10 Notes to Statements of Cash Flows 10
Page 4
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―2― 1. Qualitative Information on Quarterly Consolidated Financial Performance (1) Explanation of Results of Operations During the first quarter of the current fiscal year, the Japanese economy continued on a moderate recovery trend supported by improvements in employment and income conditions. Meanwhile, rising food and energy prices weighed on household real purchasing power, acting as a drag on personal consumption. While the number of inbound foreign visitors fell below the same period of the previous year, inbound demand remained strong due to the continuing weakening of the yen. In the global economy, downside risks to economic activity have increased due to factors such as the prolonged situation in Ukraine, escalating tensions in the Middle East, an d concerns about an economic slowdown in China, and the outlook remains uncertain. Under these circumstances, in May 2026, the Company declared its evolution into a company that promotes and realizes longevity, under the banner of “Connect for Well-being & Longevity.” By combining expertise across fields such as pharmaceuticals, skincare, food, and regenerative medicine, and building on the cell science we have cultivated since our founding, we are working daily toward the realization of a society where people can live longer, healthier, and more youthful lives. Consequently, net sales significantly increased to 91,624 million yen (up 11.8% year-on-year). In Japan, strong sales of eyecare products and skincare products, including “Hadalabo,” resulted in increased revenue. Overseas, revenue increased due to the strong performance of the Asia segment, led by Eu Yan Sang International Ltd. As for profits, operating income was 13,663 million yen (up 16.8% year -on-year), despite an increase in selling, general and administrative expenses, including advertising expenses, promotion expenses, and labor costs. Ordinary income was 14,491 million yen (down 10.1% year -on-year) and profit attributable to owners of parent was 10,650 million yen (down 9.5% year -on-year) due to a reactionary decline from the one-time dividend income recorded in the same period of the previous year. Results by reportable segment are as follows. Japan Sales to outside customers amounted to 42,864 million yen (up 5.2% year-on-year). Sales were brisk for “Hadalabo,” eye drops for young people, “Rohto V5” supplements, and “Obagi” skincare products. Among the domestic group companies, Rohto Nitten Co., Ltd., Qualitech Pharma Co., Ltd., and Amato Pharmaceutical Products, Ltd. contrib uted to sales growth. Segment profit (operating income basis) increased to 6,867 million yen (up 8.8% year-on-year) due to a portion of the originally planned advertising and R&D expenses being pushed back to the next period and beyond, as well as increased net sales at Amato Pharmaceutical Products, Ltd.. Americas Sales to outside customers amounted to 5,465 million yen (up 8.3% year-on-year). In addition to the solid performance of the US, “Hadalabo” in Brazil continued to perform strongly. Segment profit (operating income basis) significantly increased to 226 million yen (up 22.6% year-on-year) due to increased sales despite an increase in selling, general and administrative expenses. Europe Sales to outside customers increased significantly to 6,684 million yen (up 19.9% year-on-year). In addition to the strong sales of Dax Cosmetics’ “Hadalabo Tokyo” and “YOSKINE” in Poland, sales of anti -inflammatory analgesic products in the UK also recovered and performed strongly, having experienced a temporary decline in production volume in the previous fiscal year due to the bankruptcy of a container supplier. Segment profit (operating income basis) significantly increased to 664 million yen (up 392.7% year-on-year) due to strong sales of Dax Cosmetics as well as the improved cost of sales ratio in the UK resulting from the normalization of production of anti -inflammatory analgesic products.
Page 5
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―3― Asia Sales to outside customers increased significantly to 35,604 million yen (up 19.7% year-on-year). In addition to strong performances in Vietnam, Malaysia, Myanmar, and other Southeast Asian countries, Eu Yan Sang International Ltd. and China also performed solidly. Regarding the performance of particular products, eye drops, “Hadalabo,” and “Acnes” skincare products are among those that had strong sales and contributed to sales growth. Segment profit (operating income basis) significantly increased to 5,676 million yen (up 18.8% year-on-year) due to increased net sales. (2) Explanation of Financial Position Total assets at the end of the first quarter of the current fiscal year were 487,151 million yen, an increase of 1,380 millio n yen from the end of the previous fiscal year. This was mainly due to an increase of 2,739 million yen in investment securities, a n increase of 1,885 million yen in raw materials and supplies, and an increase of 1,628 million yen in retirement benefit asset, while electronically recorded monetary claims - operating decreased 4,123 million yen. Total liabilities were 158,692 million yen, a decrease of 6,904 million yen from the end of the previous fiscal year. The mai n factors were a decrease of 4,488 million yen in other under current liabilities, a decrease of 2,596 million yen in short -term borrowings, and a decrease of 2,141 million yen in income taxes payable, while notes and accounts payable - trade increased by 2,421 million yen. Net assets totaled 328,459 million yen, an increase of 8,284 million yen from the end of the previous fiscal year. This was mainly due to increases in retained earnings and foreign currency translation adjustment of 5,001 million yen and 2,435 million yen, respectively. (3) Explanation of Consolidated Earnings Forecast and Other Forward-looking Statements (Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2027) Net sales Operating income Ordinary income Profit attributable to owners of parent Net income per share Previous forecast (A) Millions of yen 369,500 Millions of yen 43,800 Millions of yen 46,100 Millions of yen 34,500 Yen 152.68 Revised forecast (B) 372,300 45,000 47,400 35,200 155.78 Change (B – A) 2,800 1,200 1,300 700 - Percentage change (%) 0.8 2.7 2.8 2.0 - The Company has revised the consolidated financial earnings forecast announced on May 13, 2026 to reflect a revision to the a ssumed exchange rates from 155 yen to 158 yen to the US dollar and from 22 yen to 23 yen to the Chinese yuan, as well as favorable performance of the Asia, Japan, and Europe segments, which exceeded expectations during the first quarter of the current fiscal year. Net sales, operating income, ordinary income and profit attributable to owners of parent are all expected to exceed the previous forecast. Net sales are also expected to increase compared to the previous fiscal year, with operating income and profit attributable to owners of parent also expected to increase. For details, please refer to the “Notice of Revision of Earnings Forecast” announced today (August 6, 2026). *The above forecasts are based on information available as of the date of announcement. Actual results may differ from the fo recasts due to various factors.
Page 6
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―4― 2. Quarterly Consolidated Financial Statements and Major Notes (1) Quarterly Consolidated Balance Sheets (Millions of yen) As of March 31, 2026 As of June 30, 2026 Assets Current assets Cash and deposits 86,816 84,771 Notes and accounts receivable - trade 52,684 50,794 Electronically recorded monetary claims - operating 24,592 20,469 Merchandise and finished goods 38,134 38,038 Work in process 5,278 5,580 Raw materials and supplies 22,265 24,151 Other 9,930 11,151 Allowance for doubtful accounts (429) (393) Total current assets 239,274 234,563 Non-current assets Property, plant and equipment Buildings and structures, net 34,255 34,467 Other, net 58,756 59,902 Total property, plant and equipment 93,011 94,369 Intangible assets Trademark right 40,152 40,170 Goodwill 34,242 34,216 Other 9,504 9,648 Total intangible assets 83,899 84,035 Investments and other assets Investment securities 55,904 58,643 Retirement benefit asset 3,046 4,674 Other 18,446 18,773 Allowance for doubtful accounts (7,899) (7,992) Total investments and other assets 69,498 74,099 Total non-current assets 246,409 252,504 Deferred assets Bond issuance costs 87 83 Total deferred assets 87 83 Total assets 485,771 487,151
Page 7
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―5― (Millions of yen) As of March 31, 2026 As of June 30, 2026 Liabilities Current liabilities Notes and accounts payable - trade 20,937 23,359 Electronically recorded obligations - operating 1,709 1,608 Short-term borrowings 24,742 22,145 Accrued expenses 22,715 22,408 Income taxes payable 6,572 4,431 Provision for bonuses 4,089 2,204 Provision for bonuses for directors (and other officers) 75 38 Other 36,507 32,018 Total current liabilities 117,349 108,214 Non-current liabilities Convertible-bond-type bonds with share acquisition rights 25,316 25,303 Long-term borrowings 2,872 2,713 Retirement benefit liability 707 2,249 Lease liabilities 7,314 7,940 Other 12,035 12,270 Total non-current liabilities 48,246 50,477 Total liabilities 165,596 158,692 Net assets Shareholders' equity Share capital 6,504 6,504 Retained earnings 256,618 261,620 Treasury shares (9,939) (9,939) Total shareholders' equity 253,183 258,185 Accumulated other comprehensive income Valuation difference on available-for-sale securities 14,285 14,523 Foreign currency translation adjustment 31,333 33,768 Remeasurements of defined benefit plans 2,643 2,627 Total accumulated other comprehensive income 48,262 50,920 Share acquisition rights 382 382 Non-controlling interests 18,346 18,970 Total net assets 320,174 328,459 Total liabilities and net assets 485,771 487,151
Page 8
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―6― (2) Quarterly Consolidated Statements of Income and Comprehensive Income Quarterly Consolidated Statements of Income For the Three-Month Period (Millions of yen) For the three months ended June 30, 2025 For the three months ended June 30, 2026 Net sales 81,964 91,624 Cost of sales 36,111 40,030 Gross profit 45,852 51,593 Selling, general and administrative expenses 34,153 37,930 Operating income 11,699 13,663 Non-operating income Interest income 237 342 Dividend income 4,106 811 Share of profit of entities accounted for using equity method 64 7 Foreign exchange gains 378 - Other 258 331 Total non-operating income 5,045 1,491 Non-operating expenses Interest expenses 316 320 Foreign exchange losses - 74 Provision of allowance for doubtful accounts 73 93 Loss on investments in investment partnerships 141 42 Other 85 133 Total non-operating expenses 617 663 Ordinary income 16,127 14,491 Extraordinary income Gain on sale of investment securities 4 311 Total extraordinary income 4 311 Extraordinary losses Loss on valuation of investment securities 1,058 - Total extraordinary losses 1,058 - Income before income taxes 15,074 14,803 Income taxes 3,021 3,754 Net income 12,052 11,048 Profit attributable to non-controlling interests 283 397 Profit attributable to owners of parent 11,769 10,650
Page 9
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―7― Quarterly Consolidated Statements of Comprehensive Income For the Three-Month Period (Millions of yen) For the three months ended June 30, 2025 For the three months ended June 30, 2026 Net income 12,052 11,048 Other comprehensive income Valuation difference on available-for-sale securities 1,046 238 Foreign currency translation adjustment (5,325) 2,657 Remeasurements of defined benefit plans, net of tax 3 (15) Share of other comprehensive income of entities accounted for using equity method (8) 0 Total other comprehensive income (4,283) 2,880 Comprehensive income 7,769 13,929 Comprehensive income attributable to Comprehensive income attributable to owners of parent 7,987 13,309 Comprehensive income attributable to non-controlling interests (217) 619
Page 10
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―8― (3) Notes to Quarterly Consolidated Financial Statements Application of Special Accounting Methods for Preparation of Quarterly Consolidated Financial Statements Calculation of tax expense Tax expense was calculated by first reasonably estimating the effective tax rate after the application of tax effect accounting with respect to income before income taxes for the fiscal year, and multiplying that rate by the quarterly income before income taxes.
Page 11
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―9― Segment Information I. Prior First Quarter (Apr. 1, 2025 – Jun. 30, 2025) 1. Information related to net sales and profit and disaggregation of revenue for each reportable segment (Millions of yen) Reportable segment (Note 1) Others (Note 2) Total Adjustment (Note 3) Reported in quarterly consolidated statement of income (Note 4) Japan Americas Europe Asia Subtotal Net sales Revenue from contracts with customers 40,757 5,044 5,572 29,743 81,119 845 81,964 － 81,964 (1) Sales to customers 40,757 5,044 5,572 29,743 81,119 845 81,964 － 81,964 (2) Inter-segment sales and transfers 1,103 373 49 1,394 2,921 40 2,961 (2,961) － Total 41,861 5,418 5,622 31,138 84,040 885 84,926 (2,961) 81,964 Segment profit 6,310 184 134 4,777 11,408 74 11,482 217 11,699 Notes: 1. "Americas" includes the business activities of overseas entities in the U.S., Brazil, and others; "Europe" those in the U.K., Poland and Austria, and others; and "Asia" those in China, Singapore, Malaysia, Vietnam, and others. 2. "Others" is the business that is excluded from reportable segments, and includes the business activities of entities in Australia. 3. "Adjustment" to segment profit of 217 million yen indicates elimination for intersegment transactions. 4. Segment profit is adjusted with operating income reported in the quarterly consolidated statement of income. 2. Information concerning impairment loss on non-current assets or goodwill by reportable segments No reportable information. II. Current First Quarter (Apr. 1, 2026 – Jun. 30, 2026) 1. Information related to net sales and profit and disaggregation of revenue for each reportable segment (Millions of yen) Reportable segment (Note 1) Others (Note 2) Total Adjustment (Note 3) Reported in quarterly consolidated statement of income (Note 4) Japan Americas Europe Asia Subtotal Net sales Revenue from contracts with customers 42,864 5,465 6,684 35,604 90,619 1,004 91,624 － 91,624 (1) Sales to customers 42,864 5,465 6,684 35,604 90,619 1,004 91,624 － 91,624 (2) Inter-segment sales and transfers 949 411 110 943 2,416 1 2,417 (2,417) － Total 43,814 5,877 6,794 36,548 93,035 1,005 94,041 (2,417) 91,624 Segment profit 6,867 226 664 5,676 13,434 37 13,472 190 13,663 Notes: 1. "Americas" includes the business activities of overseas entities in the U.S., Brazil, and others; "Europe" those in the U.K., Poland and Austria, and others; and "Asia" those in China, Singapore, Malaysia, Vietnam, and others. 2. "Others" is the business that is excluded from reportable segments, and includes the business activities of entities in Australia. 3. "Adjustment" to segment profit of 190 million yen indicates elimination for intersegment transactions. 4. Segment profit is adjusted with operating income reported in the quarterly consolidated statement of income. 2. Information concerning impairment loss on non-current assets or goodwill by reportable segments No reportable information.
Page 12
ROHTO Pharmaceutical Co., Ltd. (4527) Financial Results for the First Quarter of FY3/27 ―10― Significant Changes in Shareholders’ Equity No reportable information. Going Concern Assumption No reportable information. Notes to Statements of Cash Flows The Company has not prepared a quarterly consolidated statements of cash flows for the first quarter of the current fiscal ye ar. Depreciation (including amortization related to intangible assets other than goodwill), and amortization of goodwill for the three months ended June 30 are as shown below. (Millions of yen) For the three months ended June 30, 2025 For the three months ended June 30, 2026 Depreciation 3,579 3,950 Amortization of goodwill 506 545 * This financial report is solely a translation of “Kessan Tanshin” (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.